Articlenpj antimicrobials and resistance2026
Escalating burden and mortality of carbapenem-resistant Klebsiella pneumoniae species complex infections in Bangladeshi infants.
Article in npj antimicrobials and resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
Klebsiella pneumoniae infections in young infants are an escalating threat in low- and middle-income countries, yet robust longitudinal data integrating hospital burden, clinical outcomes, antimicrobial resistance, and genomics remains scarce. We performed an 18-year (2004-2021) prospective, multicenter genomic epidemiology study across four hospitals in Bangladesh. Among 122,353 enrolled children from whom blood and/or cerebrospinal fluid cultures were performed, 1600 (1.3%) yielded culture-confirmed Klebsiella pneumoniae species complex (KpSC) isolates. Positivity increased from 16 per 1000 cases tested in 2004 to 37 per 1000 in 2021. Hospital case-fatality rate (CFR) rose from 21.4% to 51.4% during the study, paralleling the emergence and expansion of carbapenem resistance, first detected in 2008 and reaching 81% of isolates by 2021. Neonates accounted for 80.5% of infections and experienced a CFR of 40.8%. Whole-genome sequencing of 599 representative isolates revealed four KpSC species, 145 sequence types, and 92 capsular alleles. Global high-risk clones ST11, ST16, and ST147 harbouring NDM-type carbapenemases dominated recent cases. These findings document the increasing resistance and mortality associated with KpSC infections amongst neonates in Bangladesh, underscoring the urgent need for strengthened infection prevention and control, equitable access to effective combination therapies, and vaccine-based preventative strategies.
Identifiers
42337016What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.